TABLE 2.
Type of stroke | Model | LCN2 level | Function/Clinical correlation |
Ischemic stroke | tMCAO | ↑ | LCN2 cause brain injury |
LCN2 released by injured neurons as a help me distress signal that activates microglia and astrocytes into potentially pro-recovery phenotypes. | |||
LCN2 deficiency attenuates neuroinflammation and brain injury | |||
LCN2 mainly comes from astrocytes and induce proinflammatory cytokines expression under hypoxic conditions | |||
LCN2 is an infection-related biomarker to predict clinical outcome in ischemic stroke | |||
pMCAO | ↑ | LCN2 null mice did not show any protection | |
OGD | ↑ | LCN2 induce astrocytes activation and polarization | |
Carotid artery injury | ↑ | LCN2 interacts with MMP9 may modulate MMP9 proteolytic activity in the vascular repair process | |
Hemorrhagic stroke | ICH | ↑ | LCN2 cause brain injury and up-regulation of ferritin |
LCN2 enhance PRDX2 induced brain injury | |||
Increased LCN2 may relate to clear iron after ICH | |||
Thrombin induce the expression of LCN2 through PAR-1 and cause brain injury | |||
IVH | ↑ | LCN2 promote M1 polarization in LPS induced brain injury | |
LCN2 induce high portality and more ventricular dilation | |||
SAH | ↑ | LCN2 induce whiter matter injury after SAH | |
LCN2 deletion attenuates MRI and pathological changes in whiter matter after SAH | |||
LCN2 increases early after SAH and is associated with neuroinflammation and unfavorable outcome | |||
NA | LCN2 deficiency decreased the number of cerebral thromboembolism |
tMCAO, transient middle cerebral artery occlusion; pMCAO, permanent middle cerebral artery occlusion; OGD, oxygen-glucose deprivation; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage; MMP9, matrix metallopeptidase 9; PRDX2, peroxiredoxin 2; PAR-1, protease activated receptor 1; LPS, lipopolysaccharide; NA, not applicable.